Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027

Acumen Pharmaceuticals, Inc.

Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).
Exercised option under JCR collaboration; combines Acumen's AβO antibody with J-Brain Cargo BBB-penetrating tech.
Preclinical data: 14-40x higher brain penetration in NHPs vs native antibodies; low anemia risk; no adverse events.
IND-enabling activities ongoing; IND submission targeted mid-2027; SC dosing suitability demonstrated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.